Cannabis Investment Report – Market Projections and Spending Estimates (2017)
Summary
The document is a commercial market analysis with no mention of specific individuals, transactions, or wrongdoing. It provides generic industry forecasts and spending data, offering no actionable inve Projects a 25% consumer penetration rate as a path to federal legalization. Shows projected monthly consumer spending ranging from $70 to $190 over 2016‑2030. Cites FDA approval trends for cannabis‑d
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (1)
Tags
Related Documents (6)
Ackrell Capital Cannabis Market Forecast Highlights Potential Federal Legalization Timeline
The document is a commercial market analysis with generic projections about cannabis legalization and industry growth. It contains no specific allegations, names, transactions, or actionable leads inv Projects U.S. federal cannabis legalization by 2027. Predicts California's transition to the world’s largest recreational market in 2018. Outlines expected market size growth and FDA approval trends
Ackrell Capital Cannabis Investment Report compares market size to alcohol, coffee, tobacco, and pharmaceuticals
The document is a commercial investment analysis with no mention of political figures, government agencies, or alleged misconduct. It offers no actionable leads for investigations and contains only pu Provides estimated penetration rates and consumer spending for cannabis versus other legal substance Claims U.S. legal cannabis market size aligns with other retail markets. Published by Ackrell Capi
Cannabis Investment Report – Market Size Projections and Legal Landscape (Dec 2017)
The document is a generic industry market report with no specific individuals, transactions, or allegations. It contains broad market forecasts and legal status summaries, offering no actionable inves Projects U.S. legal cannabis market to exceed $100 billion annually. Estimates global legal market potential at $500 billion annually. Notes 29 U.S. states permit medical cannabis despite federal pro
Ackrell Capital 2017 Cannabis Investment Report – Generic Market Outlook
The passage is a standard industry analysis with no specific names, transactions, dates, or allegations linking powerful actors to misconduct. It offers only broad market observations, providing minim Ackrell Capital published a December 2017 report outlining growth opportunities in cannabis‑related The report notes that large, traditional tech firms are hesitant to enter the market due to regula
Cannabis Investment Report Highlights FDA Approval Prospects and Price Trends
The passage provides market data and regulatory updates on cannabis-derived pharmaceuticals and price trends, but lacks specific allegations, financial flows, or connections to high‑profile officials. FDA may approve the first cannabis‑derived drug (Epidiolex) in 2018. GW Pharmaceuticals submitted an NDA for Epidiolex in October 2017. Sativex is approved in the UK and other countries but not in th
Cannabis Investment Report – Market Outlook and Business Solutions (Dec 2017)
The document provides generic industry analysis and investment considerations for cannabis businesses. It contains no specific references to high‑ranking officials, political actors, foreign leaders, Emphasizes building relationships with dispensary operators for shelf placement. Discusses risks and costs of obtaining FDA approval for cannabis‑derived drugs. Notes potential product liability expo
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.